News | June 02, 2021
Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
Aurobindo has one of the most enduring generics ecosystems among peers
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
This marks Glenmark's first synthetic decapeptide injectable approval
Subscribe To Our Newsletter & Stay Updated
